Javier Martín‐Broto

13.6k total citations
226 papers, 4.5k citations indexed

About

Javier Martín‐Broto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Javier Martín‐Broto has authored 226 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 189 papers in Pulmonary and Respiratory Medicine, 97 papers in Oncology and 46 papers in Gastroenterology. Recurrent topics in Javier Martín‐Broto's work include Sarcoma Diagnosis and Treatment (163 papers), Vascular Tumors and Angiosarcomas (53 papers) and Gastrointestinal Tumor Research and Treatment (46 papers). Javier Martín‐Broto is often cited by papers focused on Sarcoma Diagnosis and Treatment (163 papers), Vascular Tumors and Angiosarcomas (53 papers) and Gastrointestinal Tumor Research and Treatment (46 papers). Javier Martín‐Broto collaborates with scholars based in Spain, Italy and France. Javier Martín‐Broto's co-authors include Xavier García del Muro, Antonio López–Pousa, Andrés Poveda, Antonio Gutiérrez, Nadia Hindi, Javier Martínez‐Trufero, David S. Moura, Antonio Casado, José Antonio López‐Guerrero and Joan Maurel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

In The Last Decade

Javier Martín‐Broto

202 papers receiving 4.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Javier Martín‐Broto Spain 35 3.2k 1.6k 1.4k 1.2k 691 226 4.5k
Kirsten Sundby Hall Norway 32 2.4k 0.8× 988 0.6× 736 0.5× 1.1k 0.9× 696 1.0× 103 3.4k
James E. Butrynski United States 26 2.0k 0.6× 1.2k 0.7× 643 0.5× 506 0.4× 738 1.1× 52 3.3k
Cathryn Rankin United States 25 2.2k 0.7× 988 0.6× 1.5k 1.1× 1.1k 0.9× 208 0.3× 48 3.6k
Mary Louise Keohan United States 34 2.8k 0.9× 2.2k 1.3× 363 0.3× 354 0.3× 718 1.0× 105 4.4k
Adrián Mariño‐Enríquez United States 35 2.2k 0.7× 861 0.5× 434 0.3× 447 0.4× 1.1k 1.6× 94 3.6k
Antonio López–Pousa Spain 32 1.9k 0.6× 1.7k 1.0× 264 0.2× 804 0.7× 280 0.4× 161 3.4k
Fritz C. Eilber United States 41 3.0k 0.9× 1.8k 1.1× 141 0.1× 833 0.7× 1.0k 1.5× 121 5.0k
Masashi Takeda Japan 17 2.5k 0.8× 564 0.3× 2.7k 1.9× 1.7k 1.5× 381 0.6× 103 4.4k
Angela Cioffi France 22 1.5k 0.5× 958 0.6× 418 0.3× 384 0.3× 387 0.6× 55 2.2k
Bernadette Liegl‐Atzwanger Austria 25 1.3k 0.4× 863 0.5× 372 0.3× 528 0.5× 533 0.8× 109 2.2k

Countries citing papers authored by Javier Martín‐Broto

Since Specialization
Citations

This map shows the geographic impact of Javier Martín‐Broto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Martín‐Broto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Martín‐Broto more than expected).

Fields of papers citing papers by Javier Martín‐Broto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Martín‐Broto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Martín‐Broto. The network helps show where Javier Martín‐Broto may publish in the future.

Co-authorship network of co-authors of Javier Martín‐Broto

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Martín‐Broto. A scholar is included among the top collaborators of Javier Martín‐Broto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Martín‐Broto. Javier Martín‐Broto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Coté, Gregory M., Sant P. Chawla, George D. Demetri, et al.. (2025). SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. Future Oncology. 21(8). 943–951.
3.
Salazar, Juliana, María J. Arranz, Javier Martín‐Broto, et al.. (2024). Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 16(12). 1585–1585. 1 indexed citations
4.
5.
Blay, Jean‐Yves, Margaret von Mehren, Robin L. Jones, et al.. (2023). Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies. ESMO Open. 8(5). 101618–101618. 26 indexed citations
6.
Serrano, César, Javier Martín‐Broto, José Manuel Asencio, et al.. (2023). 2023 GEIS Guidelines for gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology. 15. 2637124–2637124. 38 indexed citations
7.
Martín‐Broto, Javier, Nadia Hindi, Giovanni Grignani, et al.. (2022). Experience with Second-Line Trabectedin in Daily Clinical Practice: Case Studies. Future Oncology. 18(sup30). 23–32. 2 indexed citations
8.
Kasper, Bernd, Lorenzo D’Ambrosio, Elizabeth J. Davis, et al.. (2022). What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?. Current Treatment Options in Oncology. 23(3). 439–449. 6 indexed citations
9.
Martín‐Broto, Javier, Andrés Redondo, David S. Moura, et al.. (2022). A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 13(1). 6278–6278. 2 indexed citations
10.
Gounder, Mrinal M., Albiruni R. Abdul Razak, Adrienne M. Gilligan, et al.. (2021). Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma. Future Oncology. 17(22). 2923–2939. 13 indexed citations
11.
Martín‐Broto, Javier & Robin L. Jones. (2021). Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies. Oncology. 99(Suppl. 1). 8–16. 1 indexed citations
12.
Obrador‐Hevia, Antònia, et al.. (2020). Cancer Stem Cells in Soft-Tissue Sarcomas. Cells. 9(6). 1449–1449. 16 indexed citations
13.
Martín‐Broto, Javier, Antonio López–Pousa, Andrew S. Brohl, et al.. (2020). Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Molecular Cancer Therapeutics. 20(1). 132–141. 9 indexed citations
14.
Alemany, Regina, David S. Moura, Andrés Redondo, et al.. (2018). Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. Clinical Cancer Research. 24(21). 5239–5249. 22 indexed citations
15.
Felipe‐Abrio, Irene, Silvia Calabuig‐Fariñas, Rafael Ramos, et al.. (2017). Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells. Molecular Cancer Therapeutics. 16(6). 1166–1176. 11 indexed citations
16.
Villanueva, Vicente, et al.. (2012). Impacto económico y en calidad de vida de la epilepsia resistente en España: estudio ESPERA. Neurología. 28(4). 195–204. 41 indexed citations
17.
Gronchi, Alessandro, S. Frustaci, Mario Mercuri, et al.. (2012). Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. Journal of Clinical Oncology. 30(8). 850–856. 120 indexed citations
18.
Villar, Víctor H., Oliver Vögler, Jordi Martínez-Serra, et al.. (2012). Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas. PLoS ONE. 7(5). e37735–e37735. 35 indexed citations
19.
Muro, Xavier García del, Antonio López–Pousa, Joan Maurel, et al.. (2011). Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. Journal of Clinical Oncology. 29(18). 2528–2533. 197 indexed citations
20.
López–Pousa, Antonio, Javier Martín‐Broto, Joaquín Montalar, et al.. (2006). Phase II Trial of Doxorubicin Plus Escalated High‐Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma. 2006(1). 26986–26986. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kirsten Sundby Hall Breakdown of academic impact, for papers by James E. Butrynski Breakdown of academic impact, for papers by Cathryn Rankin Breakdown of academic impact, for papers by Mary Louise Keohan Breakdown of academic impact, for papers by Adrián Mariño‐Enríquez Breakdown of academic impact, for papers by Antonio López–Pousa Breakdown of academic impact, for papers by Fritz C. Eilber Breakdown of academic impact, for papers by Masashi Takeda Breakdown of academic impact, for papers by Angela Cioffi Breakdown of academic impact, for papers by Bernadette Liegl‐Atzwanger
Rankless by CCL
2026